全文获取类型
收费全文 | 51854篇 |
免费 | 3654篇 |
国内免费 | 240篇 |
专业分类
耳鼻咽喉 | 514篇 |
儿科学 | 1901篇 |
妇产科学 | 1367篇 |
基础医学 | 7859篇 |
口腔科学 | 781篇 |
临床医学 | 4884篇 |
内科学 | 11333篇 |
皮肤病学 | 1171篇 |
神经病学 | 5836篇 |
特种医学 | 1172篇 |
外科学 | 4449篇 |
综合类 | 284篇 |
一般理论 | 43篇 |
预防医学 | 4646篇 |
眼科学 | 858篇 |
药学 | 4021篇 |
中国医学 | 132篇 |
肿瘤学 | 4497篇 |
出版年
2023年 | 617篇 |
2022年 | 458篇 |
2021年 | 1654篇 |
2020年 | 1367篇 |
2019年 | 1757篇 |
2018年 | 1958篇 |
2017年 | 1608篇 |
2016年 | 1729篇 |
2015年 | 1906篇 |
2014年 | 2472篇 |
2013年 | 3116篇 |
2012年 | 4587篇 |
2011年 | 4580篇 |
2010年 | 2429篇 |
2009年 | 2084篇 |
2008年 | 3464篇 |
2007年 | 3459篇 |
2006年 | 3123篇 |
2005年 | 2846篇 |
2004年 | 2631篇 |
2003年 | 2343篇 |
2002年 | 2113篇 |
2001年 | 237篇 |
2000年 | 183篇 |
1999年 | 245篇 |
1998年 | 262篇 |
1997年 | 217篇 |
1996年 | 158篇 |
1995年 | 183篇 |
1994年 | 189篇 |
1993年 | 147篇 |
1992年 | 112篇 |
1991年 | 102篇 |
1990年 | 78篇 |
1989年 | 84篇 |
1988年 | 85篇 |
1987年 | 74篇 |
1986年 | 72篇 |
1985年 | 68篇 |
1984年 | 96篇 |
1983年 | 72篇 |
1982年 | 79篇 |
1981年 | 68篇 |
1980年 | 60篇 |
1979年 | 42篇 |
1978年 | 38篇 |
1977年 | 35篇 |
1976年 | 30篇 |
1974年 | 29篇 |
1968年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Alterio Daniela La Rocca Eliana Volpe Stefania Camarda Anna Maria Casbarra Alessia Russell-Edu William Zerella Maria Alessia Orecchia Roberto Galimberti Viviana Veronesi Paolo Leonardi Maria Cristina Jereczek-Fossa Barbara Alicja 《Breast cancer research and treatment》2022,192(2):249-263
Breast Cancer Research and Treatment - To critically review available literature on hypofractionated (≥?3 Gy/fraction) proton therapy (PT) for breast cancer (BCa). A systematic... 相似文献
2.
Anna Maria Spera 《World Journal of Virology》2022,11(5):275-282
With a 5.3% of the global population involved, hepatitis B virus (HBV) is a major public health challenge requiring an urgent response. After a possible acute phase, the natural history of HBV infection can progress in chronicity. Patients with overt or occult HBV infection can undergo HBV reactivation (HBVr) in course of immunosuppressive treatments that, apart from oncological and hem-atological diseases, are also used in rheumatologic, gastrointestinal, neurological and dermatological settings, as well as to treat severe acute respiratory syndrome coronavirus 2 infection. The risk of HBV reactivation is related to the immune status of the patient and the baseline HBV infection condition. The aim of the present paper is to investigate the risk of HBVr in those not oncological settings in order to suggest strategies for preventing and treating this occurrence. The main studies about HBVr for patients with occult hepatitis B infection and chronic HBV infection affected by non-oncologic diseases eligible for immunosuppressive treatment have been analyzed. The occurrence of this challenging event can be reduced screening the population eligible for immunosuppressant to assess the best strategies according to any virological status. Further prospective studies are needed to increase data on the risk of HBVr related to newer immunomodulant agents employed in non-oncological setting. 相似文献
3.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
4.
Anna Ugalde BA PhD Victoria White BA MA PhD Nicole M. Rankin BA MSc PhD Christine Paul BA PhD Catherine Segan BA PhD Sanchia Aranda RN BAppSci MN PhD Anna Wong Shee BSc BAppSc PhD Alison M. Hutchinson RN BApp Sci MBioth PhD Patricia M. Livingston BA PhD 《CA: a cancer journal for clinicians》2022,72(3):266-286
Smoking cessation reduces the risk of death, improves recovery, and reduces the risk of hospital readmission. Evidence and policy support hospital admission as an ideal time to deliver smoking-cessation interventions. However, this is not well implemented in practice. In this systematic review, the authors summarize the literature on smoking-cessation implementation strategies and evaluate their success to guide the implementation of best-practice smoking interventions into hospital settings. The CINAHL Complete, Embase, MEDLINE Complete, and PsycInfo databases were searched using terms associated with the following topics: smoking cessation, hospitals, and implementation. In total, 14,287 original records were identified and screened, resulting in 63 eligible articles from 56 studies. Data were extracted on the study characteristics, implementation strategies, and implementation outcomes. Implementation outcomes were guided by Proctor and colleagues' framework and included acceptability, adoption, appropriateness, cost, feasibility, fidelity, penetration, and sustainability. The findings demonstrate that studies predominantly focused on the training of staff to achieve implementation. Brief implementation approaches using a small number of implementation strategies were less successful and poorly sustained compared with well resourced and multicomponent approaches. Although brief implementation approaches may be viewed as advantageous because they are less resource-intensive, their capacity to change practice in a sustained way lacks evidence. Attempts to change clinician behavior or introduce new models of care are challenging in a short time frame, and implementation efforts should be designed for long-term success. There is a need to embrace strategic, well planned implementation approaches to embed smoking-cessation interventions into hospitals and to reap and sustain the benefits for people who smoke. 相似文献
5.
Bertrand Isidor Frédéric Ebstein Anna Hurst Marie Vincent Ingrid Bader Natasha L. Rudy Benjamin Cogne Johannes Mayr Anja Brehm Caleb Bupp Kathryn Warren Carlos A. Bacino Amanda Gerard Judith D. Ranells Kay A. Metcalfe Yolande van Bever Yong-Hui Jiang Bryce A. Mendelssohn PaweƗ Stankiewicz 《Genetics in medicine》2022,24(1):179-191
PurposeHaploinsufficiency of PSMD12 has been reported in individuals with neurodevelopmental phenotypes, including developmental delay/intellectual disability (DD/ID), facial dysmorphism, and congenital malformations, defined as Stankiewicz-Isidor syndrome (STISS). Investigations showed that pathogenic variants in PSMD12 perturb intracellular protein homeostasis. Our objective was to further explore the clinical and molecular phenotypic spectrum of STISS.MethodsWe report 24 additional unrelated patients with STISS with various truncating single nucleotide variants or copy-number variant deletions involving PSMD12. We explore disease etiology by assessing patient cells and CRISPR/Cas9-engineered cell clones for various cellular pathways and inflammatory status.ResultsThe expressivity of most clinical features in STISS is highly variable. In addition to previously reported DD/ID, speech delay, cardiac and renal anomalies, we also confirmed preaxial hand abnormalities as a feature of this syndrome. Of note, 2 patients also showed chilblains resembling signs observed in interferonopathy. Remarkably, our data show that STISS patient cells exhibit a profound remodeling of the mTORC1 and mitophagy pathways with an induction of type I interferon-stimulated genes.ConclusionWe refine the phenotype of STISS and show that it can be clinically recognizable and biochemically diagnosed by a type I interferon gene signature. 相似文献
6.
7.
Zahraa Al-Hilli Anna Weiss Ava Armani Judy C Boughey Sarah L. Blair 《Journal of surgical oncology》2022,125(1):7-16
Surgical trials in breast cancer have catalyzed contemporary trial design for solid organ cancers and are a prime example of surgeons taking the lead in clinical trial design. Surgeons have lead trials that have improved patient outcomes and quality of life without sacrificing oncologic safety. We have evolved from radical mastectomy to breast conservation and sentinel node biopsy. Contemporary trial design in breast cancer now focus on personalizing care based on tumor genomics 相似文献
8.
9.